S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley, Adoptive cell transfer: a clinical path to effective cancer immunotherapy, Nature Reviews Cancer, vol.17, issue.4, pp.299-308, 2008.
DOI : 10.1038/nrc2355

G. P. Dunn, L. J. Old, and R. D. Schreiber, The Immunobiology of Cancer Immunosurveillance and Immunoediting, Immunity, vol.21, issue.2, pp.137-148, 2004.
DOI : 10.1016/j.immuni.2004.07.017

H. T. Khong and N. P. Restifo, Natural selection of tumor variants in the generation of ???tumor escape??? phenotypes, Nature Immunology, vol.3, issue.11, pp.999-1005, 2002.
DOI : 10.1038/ni1102-999

T. S. Park, S. A. Rosenberg, and R. A. Morgan, Treating cancer with genetically engineered T cells, Trends in Biotechnology, vol.29, issue.11, pp.550-557, 2011.
DOI : 10.1016/j.tibtech.2011.04.009

G. Gross, T. Waks, and Z. Eshhar, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity., Proc. Natl. Acad. Sci. USA, pp.10024-10028, 1989.
DOI : 10.1073/pnas.86.24.10024

B. Jena, G. Dotti, and L. J. Cooper, Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor, Blood, vol.116, issue.7, pp.1035-1044, 2010.
DOI : 10.1182/blood-2010-01-043737

H. M. Finney, A. N. Akbar, and A. D. Lawson, Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCR?? Chain, The Journal of Immunology, vol.172, issue.1, pp.172-104, 2004.
DOI : 10.4049/jimmunol.172.1.104

M. H. Kershaw, J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar et al., A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer, Clinical Cancer Research, vol.12, issue.20, pp.6106-6115, 2006.
DOI : 10.1158/1078-0432.CCR-06-1183

C. Hamers-casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers et al., Naturally occurring antibodies devoid of light chains, Nature, vol.363, issue.6428, pp.446-448, 1993.
DOI : 10.1038/363446a0

H. Revets, P. De-baetselier, and S. Muyldermans, Nanobodies as novel agents for cancer therapy, Expert Opin, Biol. Ther, vol.5, pp.111-124, 2005.

M. M. Harmsen, H. J. De, and . Haard, Properties, production, and applications of camelid single-domain antibody fragments, Applied Microbiology and Biotechnology, vol.77, issue.1, pp.13-22, 2007.
DOI : 10.1007/s00253-007-1142-2

A. Thor, N. Ohuchi, C. A. Szpak, W. W. Johnston, and J. Schlom, Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72, Cancer Res, vol.3, issue.46, pp.3118-3124, 1986.

A. Hombach, C. Heuser, R. Sircar, T. Tillmann, V. Diehl et al., T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope, Gastroenterology, vol.113, issue.4, pp.1163-1170, 1997.
DOI : 10.1053/gast.1997.v113.pm9322511

R. P. Mcguinness, Y. Ge, S. D. Patel, S. V. Kashmiri, H. S. Lee et al., Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor, Hum, Gene Ther, pp.10-165, 1999.

D. Friedmann-morvinski and Z. Eshhar, Adoptive immunotherapy of cancer using effector lymphocytes redirected with antibody specificity, Update on Cancer Therapeutics, vol.1, issue.1, pp.25-32, 2006.
DOI : 10.1016/j.uct.2006.04.005

E. Halapi, Oligoclonal T cells in human cancer, Medical Oncology, vol.8, issue.4, pp.203-211, 1998.
DOI : 10.1007/BF02787202

S. Derniame, J. M. Vignaud, G. C. Faure, M. C. Béné, and F. Massin, Comparative T-cell oligoclonality in lung, tumor and lymph nodes in human non-small cell lung cancer, Oncology Reports, pp.13-509, 2005.
DOI : 10.3892/or.13.3.509

A. Heiser, M. A. Maurice, D. R. Yancey, N. Z. Wu, P. Dahm et al., Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA, The Journal of Immunology, vol.166, issue.5, 2001.
DOI : 10.4049/jimmunol.166.5.2953

D. Ahmadvand, M. J. Rasaee, F. Rahbarizadeh, R. E. Kontermann, and F. Sheikholislami, Cell selection and characterization of a novel human endothelial cell specific nanobody, Molecular Immunology, vol.46, issue.8-9, pp.46-1814, 2009.
DOI : 10.1016/j.molimm.2009.01.021

J. D. Beatty, B. G. Beatty, and W. G. Vlahos, Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay, Journal of Immunological Methods, vol.100, issue.1-2, pp.173-179, 1987.
DOI : 10.1016/0022-1759(87)90187-6

F. J. Iri-sofla, F. Rahbarizadeh, D. Ahmadvand, and M. J. Rasaee, Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase, Experimental Cell Research, vol.317, issue.18, pp.317-2630, 2011.
DOI : 10.1016/j.yexcr.2011.08.015

S. Khaleghi, F. Rahbarizadeh, D. Ahmadvand, M. J. Rasaee, and P. Pognonec, A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells, International Journal of Hematology, vol.28, issue.4, pp.95-434, 2012.
DOI : 10.1007/s12185-012-1037-6

L. Jost, J. Kirkwood, and T. Whiteside, Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells, Journal of Immunological Methods, vol.147, issue.2, pp.153-165, 1992.
DOI : 10.1016/S0022-1759(12)80003-2

J. Maher, R. J. Brentjens, G. Gunset, I. Riviere, and M. Sadelain, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR?? /CD28 receptor, Nature Biotechnology, vol.20, issue.1, pp.70-75, 2002.
DOI : 10.1038/nbt0102-70

S. M. Palumbo, R. M. Memmott, D. J. Uribe, Y. Krotova-khan, L. H. Hurley et al., A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity, Nucleic Acids Research, vol.36, issue.6, pp.1755-1769, 2008.
DOI : 10.1093/nar/gkm1069

L. H. Wong, H. Ren, E. Williams, J. Mcghie, S. Ahn et al., Histone H3.3 incorporation provides a unique and functionally essential telomeric chromatin in embryonic stem cells, Histone H3. 3 incorporation provides a unique and functionally essential telomeric chromatin in embryonic stem cells, pp.404-414, 2009.
DOI : 10.1101/gr.084947.108

N. Ohuchi, E. Gero, S. Mori, M. Akimoto, N. Matoba et al., Clinical evaluation of CA72-4 immunoradiometric assay for serum TAG-72 antigen in patients with carcinoma, J. Tumor Marker Oncol, pp.5-6, 1990.

S. C. Semple, A. Akinc, J. Chen, A. P. Sandhu, B. L. Mui et al., Rational design of cationic lipids for siRNA delivery, Nature Biotechnology, vol.22, issue.2, pp.28-172, 2010.
DOI : 10.1038/nbt.1602

D. W. Kufe, Mucins in cancer: function, prognosis and therapy, Nature Reviews Cancer, vol.34, issue.12, pp.874-885, 2009.
DOI : 10.1038/nrc2761

J. Wesolowski, V. Alzogaray, J. Reyelt, M. Unger, K. Juarez et al., Single domain antibodies: promising experimental and therapeutic tools in infection and immunity, Medical Microbiology and Immunology, vol.7, issue.2, pp.198-157, 2009.
DOI : 10.1007/s00430-009-0116-7

M. A. Pulè, K. C. Straathof, G. Dotti, H. E. Heslop, C. M. Rooney et al., A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells, Molecular Therapy, vol.12, issue.5, pp.12-933, 2005.
DOI : 10.1016/j.ymthe.2005.04.016

V. Marin, I. Pizzitola, V. Agostoni, G. M. Attianese, H. Finney et al., Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors, Haematologica, vol.95, issue.12, pp.2144-2152, 2010.
DOI : 10.3324/haematol.2010.026310

A. A. Hombach and H. Abken, Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling, International Journal of Cancer, vol.18, issue.12, pp.2935-2944, 2011.
DOI : 10.1002/ijc.25960

C. H. Lamers, R. Willemsen, P. Van-elzakker, S. Van-steenbergen-langeveld, M. Broertjes et al., Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells, Blood, vol.117, issue.1, pp.72-82, 2011.
DOI : 10.1182/blood-2010-07-294520

A. James, S. J. Raubitschek, A. K. Forman, J. M. Gopal, C. G. Pagel et al., Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood, vol.112, pp.2261-2271, 2008.

E. J. Beecham, S. Ortiz-pujols, and R. P. Junghans, Dynamics of Tumor Cell Killing by Human T Lymphocytes Armed With an Anti-Carcinoembryonic Antigen Chimeric Immunoglobulin T-Cell Receptor, Journal of Immunotherapy, vol.23, issue.3, pp.332-343, 2000.
DOI : 10.1097/00002371-200005000-00006

A. Hombach, J. M. Muche, M. Gerken, S. Gellrich, C. Heuser et al., T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells, Gene Therapy, vol.8, issue.11, pp.891-895, 2001.
DOI : 10.1038/sj.gt.3301467

F. A. Harding, M. M. Stickler, J. Razo, and R. B. Dubridge, The immunogenicity of humanized and fully human antibodies, mAbs, vol.23, issue.3, pp.256-265, 2010.
DOI : 10.1093/annonc/mdm399

V. Cortez-retamozo, M. Lauwereys, G. Hassanzadeh-gh, M. Gobert, K. Conrath et al., Efficient tumor targeting by single-domain antibody fragments of camels, International Journal of Cancer, vol.78, issue.3, pp.456-462, 2002.
DOI : 10.1002/ijc.10212

K. Coppieters, T. Dreier, K. Silence, H. De-haard, M. Lauwereys et al., Formatted anti???tumor necrosis factor ?? VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis, Arthritis & Rheumatism, vol.98, issue.6, pp.1856-1866, 2006.
DOI : 10.1002/art.21827

T. N. Schumacher, T-cell-receptor gene therapy, Nature Reviews Immunology, vol.2, issue.7, pp.512-519, 2002.
DOI : 10.1038/nri841

N. Bitton, F. Verrier, P. Debré, and G. Gorochov, Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120, European Journal of Immunology, vol.94, issue.12, pp.28-4177, 1998.
DOI : 10.1002/(SICI)1521-4141(199812)28:12<4177::AID-IMMU4177>3.0.CO;2-J

E. Lanitis, M. Poussin, I. S. Hagemann, G. Coukos, R. Sandaltzopoulos et al., Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor, Molecular Therapy, vol.20, issue.3, pp.633-643, 2011.
DOI : 10.1038/mt.2011.256

T. Logtenberg, Antibody cocktails: next-generation biopharmaceuticals with improved potency, Trends in Biotechnology, vol.25, issue.9, pp.390-394, 2007.
DOI : 10.1016/j.tibtech.2007.07.005

C. Newcombe and A. R. Newcombe, Antibody production: Polyclonal-derived biotherapeutics, Journal of Chromatography B, vol.848, issue.1, pp.2-7, 2007.
DOI : 10.1016/j.jchromb.2006.07.004

E. Sadeqzadeh, F. Rahbarizadeh, D. Ahmadvand, M. J. Rasaee, L. Parhamifar et al., Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells, Journal of Controlled Release, vol.156, issue.1, pp.156-85, 2011.
DOI : 10.1016/j.jconrel.2011.06.022